CureVac (NASDAQ: CVAC) files Form 6-K with unaudited interim H1 2025 data

Rhea-AI Filing Summary

CureVac N.V. submitted a Form 6-K to provide investors with updated mid‑year information. The filing furnishes unaudited interim condensed consolidated financial statements as of June 30 and for the three and six months ended June 30, 2025 and 2024. It also includes a Management’s Discussion and Analysis of financial condition and results of operations for the six‑month periods ended June 30, 2025 and 2024, offering narrative context around the company’s performance and business updates.

00018091222025-01-012025-06-300001809122cvac:BiontechSEMembercvac:CurevacNVMemberifrs-full:TopOfRangeMembersrt:ScenarioForecastMember2025-06-122025-06-120001809122cvac:BiontechSEMembercvac:CurevacNVMemberifrs-full:BottomOfRangeMembersrt:ScenarioForecastMember2025-06-122025-06-120001809122cvac:CrisprMember2025-04-012025-06-300001809122cvac:CrisprMember2025-01-012025-06-300001809122cvac:GlaxosmithklineMember2024-04-012024-06-300001809122cvac:CrisprMember2024-04-012024-06-300001809122cvac:GlaxosmithklineMember2024-01-012024-06-300001809122cvac:CrisprMember2024-01-012024-06-300001809122cvac:ResearchAndDevelopmentServicesMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2025-04-012025-06-300001809122cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2025-04-012025-06-300001809122country:CHcvac:CrisprMember2025-04-012025-06-300001809122country:BEcvac:GlaxosmithklineMember2025-04-012025-06-300001809122ifrs-full:GoodsOrServicesTransferredOverTimeMember2025-04-012025-06-300001809122cvac:ResearchAndDevelopmentServicesMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2025-01-012025-06-300001809122cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2025-01-012025-06-300001809122cvac:IfrsProductMemberifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2025-01-012025-06-300001809122country:CHcvac:CrisprMember2025-01-012025-06-300001809122country:BEcvac:GlaxosmithklineMember2025-01-012025-06-300001809122ifrs-full:GoodsOrServicesTransferredOverTimeMember2025-01-012025-06-300001809122ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2025-01-012025-06-300001809122cvac:ResearchAndDevelopmentServicesMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2024-04-012024-06-300001809122cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2024-04-012024-06-300001809122cvac:IfrsProductMemberifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2024-04-012024-06-300001809122cvac:GlaxosmithklineMembercvac:ResearchAndDevelopmentServicesMember2024-04-012024-06-300001809122country:CHcvac:CrisprMember2024-04-012024-06-300001809122country:BEcvac:GlaxosmithklineMember2024-04-012024-06-300001809122ifrs-full:GoodsOrServicesTransferredOverTimeMember2024-04-012024-06-300001809122ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2024-04-012024-06-300001809122cvac:ResearchAndDevelopmentServicesMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2024-01-012024-06-300001809122cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2024-01-012024-06-300001809122cvac:IfrsProductMemberifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2024-01-012024-06-300001809122cvac:GlaxosmithklineMembercvac:ResearchAndDevelopmentServicesMember2024-01-012024-06-300001809122cvac:CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMembercvac:GlaxosmithklineMember2024-01-012024-06-300001809122country:CHcvac:CrisprMember2024-01-012024-06-300001809122country:BEcvac:GlaxosmithklineMember2024-01-012024-06-300001809122ifrs-full:GoodsOrServicesTransferredOverTimeMember2024-01-012024-06-300001809122ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2024-01-012024-06-300001809122cvac:BiontechSEMembercvac:CurevacNVMembersrt:ScenarioForecastMember2025-06-122025-06-120001809122ifrs-full:PreferenceSharesMember2025-06-300001809122ifrs-full:OrdinarySharesMember2025-06-300001809122ifrs-full:ShareOptionsMembercvac:SupervisoryBoardMembersMember2025-02-242025-02-240001809122ifrs-full:ShareOptionsMembercvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember2025-02-242025-02-240001809122ifrs-full:ShareOptionsMembercvac:KeyEmployeesMember2025-01-012025-01-010001809122cvac:SellingAndDistributionExpensesMember2025-04-012025-06-300001809122cvac:OtherOperatingExpensesMember2025-04-012025-06-300001809122cvac:SellingAndDistributionExpensesMember2025-01-012025-06-300001809122cvac:OtherOperatingExpensesMember2025-01-012025-06-300001809122cvac:SellingAndDistributionExpensesMember2024-04-012024-06-300001809122cvac:OtherOperatingExpensesMember2024-04-012024-06-300001809122cvac:SellingAndDistributionExpensesMember2024-01-012024-06-300001809122cvac:OtherOperatingExpensesMember2024-01-012024-06-300001809122ifrs-full:RetainedEarningsMember2025-06-300001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-06-300001809122ifrs-full:IssuedCapitalMember2025-06-300001809122ifrs-full:CapitalReserveMember2025-06-300001809122ifrs-full:RetainedEarningsMember2024-12-310001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-12-310001809122ifrs-full:IssuedCapitalMember2024-12-310001809122ifrs-full:CapitalReserveMember2024-12-310001809122ifrs-full:RetainedEarningsMember2024-06-300001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-06-300001809122ifrs-full:IssuedCapitalMember2024-06-300001809122ifrs-full:CapitalReserveMember2024-06-300001809122ifrs-full:RetainedEarningsMember2023-12-310001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-12-310001809122ifrs-full:IssuedCapitalMember2023-12-310001809122ifrs-full:CapitalReserveMember2023-12-310001809122cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember2025-01-012025-06-300001809122cvac:KeyEmployeesMember2025-01-012025-06-300001809122ifrs-full:RetainedEarningsMember2025-01-012025-06-300001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-01-012025-06-300001809122ifrs-full:RetainedEarningsMember2024-01-012024-06-300001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-01-012024-06-300001809122cvac:CurevacNVMember2025-08-310001809122cvac:LongTermIncentivePlanMembercvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember2025-02-242025-02-240001809122cvac:LongTermIncentivePlanMembercvac:KeyEmployeesMember2025-01-012025-01-010001809122cvac:GlaxosmithklineMember2025-06-300001809122cvac:CrisprMember2025-06-3000018091222020-11-302020-11-3000018091222025-01-012025-03-3100018091222024-01-012024-03-310001809122ifrs-full:IssuedCapitalMember2025-01-012025-06-300001809122ifrs-full:IssuedCapitalMember2024-01-012024-06-300001809122cvac:GlaxosmithklineMember2025-08-310001809122ifrs-full:CapitalReserveMember2025-01-012025-06-300001809122ifrs-full:CapitalReserveMember2024-01-012024-06-300001809122ifrs-full:CostOfSalesMember2025-04-012025-06-300001809122ifrs-full:CostOfSalesMember2025-01-012025-06-300001809122cvac:LargestShareholderMember2025-06-300001809122cvac:GlaxosmithklineMember2025-08-012025-08-310001809122cvac:CurevacNVMember2025-08-012025-08-310001809122ifrs-full:LegalProceedingsProvisionMember2024-07-012024-07-310001809122ifrs-full:LegalProceedingsProvisionMember2024-05-012024-05-310001809122cvac:BiontechSEMember2025-06-1200018091222025-06-1200018091222020-11-300001809122cvac:BiontechSEMembercvac:CurevacNVMembersrt:ScenarioForecastMember2025-06-120001809122cvac:IfrsResearchAndDevelopmentExpenseMember2025-04-012025-06-300001809122cvac:IfrsGeneralAndAdministrativeExpenseMember2025-04-012025-06-300001809122cvac:IfrsResearchAndDevelopmentExpenseMember2025-01-012025-06-300001809122cvac:IfrsGeneralAndAdministrativeExpenseMember2025-01-012025-06-300001809122ifrs-full:CostOfSalesMember2024-04-012024-06-300001809122cvac:IfrsResearchAndDevelopmentExpenseMember2024-04-012024-06-300001809122cvac:IfrsGeneralAndAdministrativeExpenseMember2024-04-012024-06-300001809122ifrs-full:CostOfSalesMember2024-01-012024-06-300001809122cvac:IfrsResearchAndDevelopmentExpenseMember2024-01-012024-06-300001809122cvac:IfrsGeneralAndAdministrativeExpenseMember2024-01-012024-06-3000018091222024-01-012024-12-310001809122cvac:BiontechSEMembercvac:CurevacNVMemberdei:AdrMembersrt:ScenarioForecastMember2025-06-120001809122ifrs-full:ShareOptionsMember2025-04-012025-06-300001809122cvac:RsuSupervisoryBoardMember2025-04-012025-06-300001809122cvac:LongTermIncentivePlanAndRestrictedStockUnitMember2025-04-012025-06-3000018091222025-04-012025-06-300001809122ifrs-full:ShareOptionsMember2025-01-012025-06-300001809122cvac:RsuSupervisoryBoardMember2025-01-012025-06-300001809122cvac:LongTermIncentivePlanAndRestrictedStockUnitMember2025-01-012025-06-300001809122ifrs-full:ShareOptionsMember2024-04-012024-06-300001809122cvac:RsuSupervisoryBoardMember2024-04-012024-06-300001809122cvac:PriorVirtualStockOptionsPlanMember2024-04-012024-06-300001809122cvac:LongTermIncentivePlanAndRestrictedStockUnitMember2024-04-012024-06-3000018091222024-04-012024-06-300001809122ifrs-full:ShareOptionsMember2024-01-012024-06-300001809122cvac:RsuSupervisoryBoardMember2024-01-012024-06-300001809122cvac:PriorVirtualStockOptionsPlanMember2024-01-012024-06-300001809122cvac:LongTermIncentivePlanAndRestrictedStockUnitMember2024-01-012024-06-3000018091222025-06-3000018091222025-03-3100018091222024-12-3100018091222024-06-3000018091222024-03-3100018091222023-12-310001809122cvac:CurevacNVMember2025-06-120001809122ifrs-full:LegalProceedingsProvisionMember2024-01-012024-06-3000018091222024-01-012024-06-30iso4217:EURiso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:purecvac:itemiso4217:EURxbrli:sharescvac:Ycvac:Option

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 6-K

​

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

​

For the month of August 2025

Commission File Number: 001-39446

​

CureVac N.V.

(Exact Name of Registrant as Specified in Its Charter)

​

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

​

Form 20-F ☒ Form 40-F ☐

​

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

​

Yes ☐ No ☒

​

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

​

Yes ☐ No ☒

​

​

​

​

​

​

This Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) is being furnished by CureVac N.V. (“CureVac”) to the Securities and Exchange Commission (the “SEC”) for the sole purposes of: (i) furnishing, as Exhibit 99.1 to this Form 6-K, Unaudited Interim Condensed Consolidated Financial Statements announcing CureVac’s financial results and business updates as of June 30, and for the three and six months ended June 30, 2025 and 2024; and (ii) furnishing, as Exhibit 99.2 to this Form 6-K, Management’s Discussion and Analysis of Financial Condition and Results of Operations, which discusses and analyzes CureVac’s financial condition and results of operations as of June 30, 2025 and for the six month periods ended June 30, 2025 and 2024.

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​		​	​	​
CUREVAC N.V.			​
​		​	​	​
By:	/s/Axel Sven Malkomes	​	By:	/s/Alexander Zehnder
​	Chief Financial Officer	​	​	Chief Executive Officer
​		​	​	​
​		​	​	​
Date: August 15, 2025		​	​	​

​

​

​

​

EXHIBIT INDEX

​

EXHIBIT NO.		DESCRIPTION
99.1		Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2025 and for the three and six months ended June 30, 2025 and 2024
99.2	​	Management’s Discussion and Analysis of Financial Condition and Results of Operations

​

​

​

FAQ

What does CureVac (CVAC) report in its August 2025 Form 6-K?

CureVac’s Form 6-K furnishes unaudited interim condensed consolidated financial statements and management’s discussion and analysis for periods ended June 30, 2025 and 2024, providing updated mid‑year financial and operational information to investors.

Which periods are covered by CureVac’s interim financial statements on Form 6-K?

The interim condensed consolidated financial statements cover CureVac’s results as of June 30 and for the three and six months ended June 30, 2025 and 2024, giving a comparative mid‑year view across two fiscal years.

What is included in CureVac (CVAC) Exhibit 99.1 to the Form 6-K?

Exhibit 99.1 contains CureVac’s unaudited interim condensed consolidated financial statements as of June 30, 2025 and for the three and six months ended June 30, 2025 and 2024, detailing the company’s mid‑year financial position and performance.

What is included in CureVac (CVAC) Exhibit 99.2 to the Form 6-K?

Exhibit 99.2 provides Management’s Discussion and Analysis of Financial Condition and Results of Operations for CureVac as of June 30, 2025 and for the six‑month periods ended June 30, 2025 and 2024, explaining trends and key business updates.

Who signed CureVac’s August 2025 Form 6-K filing?

The Form 6-K was signed on behalf of CureVac N.V. by Chief Financial Officer Axel Sven Malkomes and Chief Executive Officer Alexander Zehnder, reflecting executive authorization of the submitted interim information.

Is CureVac’s Form 6-K information audited or unaudited?

The interim condensed consolidated financial statements furnished in CureVac’s Form 6-K are unaudited, providing timely mid‑year financial data ahead of any audited annual reporting cycle.